Abstract: Use of a compound of the formula wherein Base is thymine, Cytosine, adenine or guanine, or a physiologically acceptable salt thereof, for therapeutic or prophylactic control or treatment of retrovirus infections, including HIV, and hepatitis B virus infections and to a method for such treatment, especially for AIDS.

Abstract: Antivirally active compounds of formula (I), wherein R.sup.1 is hydrogen, hydroxy, mercapto or amino; R.sup.2 is hydrogen, hydroxy, fluoro, chloro or amino; R.sup.3 and R.sup.4 are independently selected from (II), (III), amino, hydroxy or an ether or ester residue thereof, or R.sup.3 together with R.sup.4 is (IV), wherein M is hydrogen or a pharmaceutically acceptable counterion; and n is 1 or 2; with the proviso that, when R.sup.2 is amino and R.sup.3 and R.sup.4 are hydroxy, R.sup.1 is not hydroxy and in addition, when n=1, R.sup.1 is not hydrogen, and pharmaceutically acceptable salts thereof; processes for preparation of said compounds, a pharmaceutical composition comprising said compounds, methods for treatments of virus infections as well as use of compounds of formula (I) without the proviso for the manufacture of a medicament for treatment of AIDS.

Abstract: A method for producing the Folliculotropin Releasing Hormone (FRH) biosynthetically is provided by utilizing, as key starting materials, fresh hypothalamic tissue, a buffered incubation medium, an ATP synthesizing system, radioactively labeled amino acids and a mixture of 21 naturally occuring amino acids. Biosynthesis of the FRH is accomplished by incubation of the hypothalamic tissue for a short period of time in the presence of all the reagents necessary to promote the biosynthetic system to produce the Folliculotropin Releasing Hormone (FRH) of the hypothalamus gland of mammals. Examples of methods to isolate the FRH free of the luteotropin releasing hormone (LRH) are provided.